Voxilaprevir

Phase 1Small molecule

Voxilaprevir is one of 48 small molecule programs targeting Chronic Hepatitis C Virus Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis C Virus InfectionActive, not recruiting

Chronic Hepatitis C Virus InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Chronic Hepatitis C Virus Infection

#DrugCompanyPhaseTrials

Avapro

Lescol

Plaquenil

Alnylam Pharmaceuticals

Actigall

Neoral

Nolvadex

Incivek

Vertex Pharmaceuticals

Phase 3

4 8

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

—9

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Approved

—10

Alinia

RRomark Laboratories L.C.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis C Virus Infection2 trials

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Terminated·MM.D. Anderson Cancer Center·Phase 4·NCT05717400·2 enrolled

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Completed· Gilead logo

Gilead·Phase 1·NCT02185794·101 enrolled

Hepatic Impairment1 trial

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Completed· Gilead logo

Gilead·Phase 1·NCT02397707·33 enrolled

Renal Impairment1 trial

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

Completed· Gilead logo

Gilead·Phase 1·NCT02402452·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Voxilaprevir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Voxilaprevir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Voxilaprevir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Gilead

Voxilaprevir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis C Virus Infection2 trials

Hepatic Impairment1 trial

Renal Impairment1 trial

References

Drug Info

Quick Facts

Related News